Based on 2 analysts offering 12 month price targets for Vivos Therapeutics Inc
Min Forecast
$6.00+172.73%
Avg Forecast
$6.10+177.27%
Max Forecast
$6.20+181.82%
Should I buy or sell VVOS stock?
Based on 2 analysts offering ratings for Vivos Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VVOS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VVOS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More
Be the first to know when Wall Street analysts revise their VVOS stock forecasts and price targets.
Is Vivos Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: VVOS) stock is to Strong Buy VVOS stock.
Out of 2 analysts, 1 (50%) are recommending VVOS as a Strong Buy, 1 (50%) are recommending VVOS as a Buy, 0 (0%) are recommending VVOS as a Hold, 0 (0%) are recommending VVOS as a Sell, and 0 (0%) are recommending VVOS as a Strong Sell.
What is VVOS's earnings growth forecast for 2025-2025?
(NASDAQ: VVOS) Vivos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Vivos Therapeutics's earnings in 2025 is -$11,136,000.
In 2025, VVOS is forecast to generate -$8,422,014 in earnings, with the lowest earnings forecast at -$8,422,014 and the highest earnings forecast at -$8,422,014.
What is VVOS's revenue growth forecast for 2025-2025?
(NASDAQ: VVOS) Vivos Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Vivos Therapeutics's revenue in 2025 is $15,031,000.
In 2025, VVOS is forecast to generate $107,778,216 in revenue, with the lowest revenue forecast at $107,778,216 and the highest revenue forecast at $107,778,216.
What is VVOS's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: VVOS) forecast ROA is -55.1%, which is lower than the forecast US Medical Devices industry average of 9.53%.
What is VVOS's Price Target?
According to 2 Wall Street analysts that have issued a 1 year VVOS price target, the average VVOS price target is $6.10, with the highest VVOS stock price forecast at $6.20 and the lowest VVOS stock price forecast at $6.00.
On average, Wall Street analysts predict that Vivos Therapeutics's share price could reach $6.10 by Apr 15, 2026. The average Vivos Therapeutics stock price prediction forecasts a potential upside of 177.27% from the current VVOS share price of $2.20.
What is VVOS's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: VVOS) Vivos Therapeutics's current Earnings Per Share (EPS) is -$2.22. In 2025, VVOS's EPS is forecast to hit -$1.43 (min: -$1.43, max: -$1.43).
What is VVOS's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: VVOS) forecast ROE is -105.88%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.